Agreement Between Patient and Physician Assessment of Eyebrow and Eyelash Hair Loss in Two Phase 3 Trials Evaluating Baricitinib in Patients with Severe Alopecia Areata

Main Article Content

Justin Ko
Stanford Medicine, Stanford, USA

Amy McMichael
Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, USA

Antonella Tosti
University of Miami Miller School of Medicine, Miami, USA

Taisuke Ito
Hamamatsu University School of Medicine, Hamamatsu, Japan

Yves Dutronc
Eli Lilly and Company, Indianapolis, USA

Guanglei Yu
Eli Lilly and Company, Indianapolis, USA

Yunfei Chen
Eli Lilly and Company, Indianapolis, USA

Mwangi Murage
Eli Lilly and Company, Indianapolis, USA

Chiara Chiasserini
Eli Lilly and Company, Indianapolis, USA

Arash Mostaghimi
Brigham & Women’s Hospital, Harvard Medical School, Boston, USA

Keywords

Baricitinib, Alopecia Areata

References

1. Mesinkovska N, et al. J Investig Dermatol Symp Proc. 2020;20:S62-S68.

2. King B, et al. J Am Acad Dermatol. 2021;85:847-853.

3. King B, et al. N Engl J Med. 2022;386:1687-1699.

4. Wyrwich KW, et al. Am J Clin Dermatol. 2020;21:725-732.

Article Sidebar

PDF
Published
Nov 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.295

Article Details

How to Cite
Ko, J. ., McMichael, A. ., Tosti, A. ., Ito, T. ., Dutronc, Y. ., Yu, G. ., Chen, Y. ., Murage, M. ., Chiasserini, C. ., & Mostaghimi, A. . (2023). Agreement Between Patient and Physician Assessment of Eyebrow and Eyelash Hair Loss in Two Phase 3 Trials Evaluating Baricitinib in Patients with Severe Alopecia Areata. SKIN The Journal of Cutaneous Medicine, 7(6), s295. https://doi.org/10.25251/skin.7.supp.295
Issue
Vol. 7 No. 6 (2023): November 2023 Issue
Section
Alopecia
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)